Insulin price drop! Diabetics save about $4,000 a year

Good news for diabetic patients!

The reporter learned from the Autonomous Region Medical Security Bureau

From May 30th, Guangxi medical and health institutions

will uniformly implement the sixth batch of state-organized drugs

Selected results of centralized procurement (insulin special)

The average price of selected insulins is reduced by 48%

will reduce the burden on diabetic patients< /span>

Insulin is an important drug for the treatment of diabetes, with a large number of patients and long-term use. The results of this centralized procurement have a high level of homogeneity, which is highly matched with the actual clinical needs, covering a total of 16 generic varieties of second-generation and third-generation insulin commonly used in clinical practice. Including well-known enterprise products commonly used by medical institutions, as well as emerging enterprise products, are mature products that have been market and clinically proven.

The results of this selection were implemented, which greatly reduced the burden on patients. According to the relevant person in charge of the Medical Insurance Bureau of the autonomous region, based on the purchase volume of about 3.64 million pieces reported by Guangxi medical and health institutions in the first year, it is estimated that the region can save 105 million yuan per year.

Taking the commonly used clinical insulin glargine as an example, the average cost is reduced from 180 yuan per vial to about 70 yuan per vial before centralized collection, and a diabetic patient can save about 4,000 yuan in treatment costs per year .

This insulin centralized procurement is the first time that the state-organized centralized drug procurement has expanded from chemical drugs to biological drugs, and it is also an important milestone in the process of centralized procurement reform.

In the next step, the Autonomous Region Medical Insurance Bureau will do a solid job of listing the selected drugs on the Internet, organizing the signing of purchase and sales contracts, linking medical insurance payment policies, promoting clinical rational drug use, and strengthening supply monitoring. At the same time, it has also cooperated with relevant departments to further strengthen the monitoring and supervision of the quality and safety of the selected insulin, production and distribution, and use.